EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinic... (MD-1198 a novel antimitotic agent and EN...)

EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program

Date:4/9/2008

MD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commerci
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
2. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
3. EntreMed to Present at The New York Society of Security Analysts Industry Conference
4. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
5. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
6. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
7. EntreMed Raises $20 Million to Support Clinical Development Program
8. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
9. Bionomics Achieves US$1 Million Milestone Payment from Genmab
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus

Post Your Comments:

(Date:5/20/2013)... MINNEAPOLIS , May 20, 2013 Uroplasty, Inc. ... will release financial results for the fiscal fourth quarter ... market close on Thursday, May 30, 2013. The Company ... these results on Thursday, May 30, 2013 at 4:30 ... to participate in the conference call should dial 888-549-7750, ...

(Date:5/20/2013)... Quebec , May 20, 2013 Valeant Pharmaceuticals International, ... members of its senior management team will make a presentation ... on Tuesday, June 11, 2013 at 9:20 a.m. PT. The ... Los Angeles, CA. A live ... on the company,s Web site at www.valeant.com . Click ...

(Date:5/20/2013)... 20, 2013 /PRNewswire-iReach/ -- Today at American Society ... Christine Ginocchio discussed Specific Technologies blood ... identification of microorganisms producing bloodstream infection. Dr. Ginocchio ... the Division of Infectious Disease Diagnostics at North ... non-sectarian health system. (Photo: http://photos.prnewswire.com/prnh/20130520/CG16829 ...

Breaking Medicine Technology:Uroplasty To Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results On May 30, 2013 2 Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2 Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3

[0] Uroplasty To Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results On May 30, 2013 [0] Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference [0] Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio

... IDM Pharma, Inc.,(the Company) (Nasdaq: IDMI ) ... clinical protocol finalized with the U.S. Food and ... osteosarcoma patients through a compassionate access study., ... increasing number of,requests for compassionate access to L-MTP-PE," ...

... not the Only Way We Suffer - ... Allergies Impact Mood and Self-Perception, KENILWORTH, N.J. and ... about 50,million people in the United States.(1)(2) Yet, according to ... a nuisance: in today,s society allergies get little respect.,As a ...

Cached Medicine Technology:IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 2 IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 3 IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 4 IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 5 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 2 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 3 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 4 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 5 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 6 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 7

IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly

(Date:5/20/2013)... Mombo from Comfort & Harmony ... US Lactation Consultant Association (USLCA) May 2nd – 5th. ... other health professionals. , The USLCA annual conference ... discover and learn about the latest trends in lactation. ... nursing pillows, which new mothers use to help support ...

(Date:5/20/2013)... (PRWEB) May 21, 2013 People are so ... Stress levels are through the roof and are contributing ... handle this stress could mean the difference between life and ... Begin’ event on 29 May will share valuable, practical tools ... and influence the world around them for social good. , ...

(Date:5/20/2013)... According to a May 6, 2013 CBS News ... tanning salons in the US may soon have ... wants to see cancer warnings on indoor tanning beds ... eighteen for the use of indoor tanning and sun beds. ... become increasingly common over the last few decades (Go to ...

(Date:5/20/2013)... MI (PRWEB) May 20, 2013 ... Lupus Foundation will be holding ... in Lansing on June 10th. ... June 10th, 6:30 p.m. – ... Building (Across from Sparrow Hospital), ...

(Date:5/20/2013)... to a June 2009 Bloomberg article, it is estimated ... $3.6 billion dollars per year (i). Additionally, in ... 15 million incidents of medical harm each year (ii). ... any form of medical treatment should be aware of ... as “a dereliction of professional duty or a failure ...

Breaking Medicine News(10 mins):Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2 Health News:Chill Out and Change the World, Say Mind Experts at V Star Bliss Event in Sydney 2 Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2 Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2

[0] Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference [0] Chill Out and Change the World, Say Mind Experts at V Star Bliss Event in Sydney [0] Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs [0] Lupus Support Group Meeting in Lansing on June 10th [0] Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases

... OF MICHIGAN URGES DETROIT EMPLOYERS TO SEE INFLUENZA AS ... in billions of dollars in lost wages every year, ... missed workdays a year, and about 200 million days ... Yet vaccination rates remain alarmingly low, especially among working ...

... and continued positive cash flow from operationsBOSTON, Feb. ... ), a leader in radiology and medical image ... results for the fourth quarter and year ended ... Q4 Financial Highlights Revenue : Total revenue ...

... - Conference call on Thursday, February 26, 2009, at 9:00 ... International (NYSE: SCI ), a leading provider of ... quarter and fiscal year 2008 and provided its comments on ... statements can be found at the end of this press ...

... Pharmaceuticals to increase access to radiological threat antidoteWASHINGTON, ... agreement in principle with Fleming Pharmaceuticals for the ... ThyroShield(R) Potassium Iodide Oral Solution is a ready-to-use, ... at risk of exposure to radioactive iodine. It ...

... Feb. 25 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... live webcast on Tuesday, March 3, 2009 at 9:00 am EST ... 31, 2008. The Company will release results after the market ... be available on the Par website at www.parpharm.com .Access to ...

... growing twice as fast as San Diego.The system rewards physicians ... Feb. 25 The cost of providing health care to ... as in San Diego, and Medicare now spends nearly three ... it does in Honolulu. This illustrates how huge inefficiencies in ...

Influenza Infection Costs Employers Billions Each Year; Working Adults Largest Group Not Immunized Annually AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 Service Corporation International Announces Fourth Quarter 2008 Financial Results and Comments on Outlook for 2009 Heyltex Corporation to Become Exclusive Distributor of ThyroShield(R)Par Pharmaceutical to Host Fourth Quarter and Full Year 2008 Results Conference Call on March 3 at 9:00 am Taming Wide Variations in Spending Key to Health Reform - New England Journal of Medicine Commentary from Dartmouth Atlas Project

... membrane parasite soluble lysate ... as antigen. Since this ... than the recombinant kit, ... use two ELISA techniques ...

The Cellabs T. cruzi IgG CELISA is a direct ELISA kit designed to detect antibodies produced during T. cruzi infections (Chagas disease)....

... The dual-electrode SPL defibrillator lead ... design, offering the flexibility and ... Designed for the physician who ... shocking coils, the SPL lead ...

... The Medtronic Subcutaneous Lead ... implanted subcutaneously with the use ... Model 6996T. Improved SQ design ... DFTs, a fast and easy ...

Medicine Products:

Chagatest ELISA T. cruzi IgG CELISA SPL™ Leads Subcutaneous Lead System Model 6996SQ